Objective: to characterize the involvement of the respiratory apparatus of patients with cystic fibrosis in order to obtain a comprehensive view of their pulmonary picture.
Introduction
Cystic fibrosis is a serious hereditary disease (autosomal recessive) with incidence of 1:2000 births. 1 Genetic mutations on the cystic fibrosis transmembrane conductance regulator (CFTR) gene, located on the long arm of chromosome 7, at 7q31, cause functional problems of the protein it encodes. This protein contains 1,480 amino acids and controls the chloride channel regulated by the cyclic adenosine monophosphate protein (cAMP), present on the surface of epithelial cells. Three hundred fifty mutations have been identified in this gene, but the most common is the ∆F508, which indicates the deletion of three base pairs and results in the absence of phenylalanine in position 508 of the amino acid sequence. 2 Some of the most characteristic features of cystic fibrosis are: malabsorption syndrome resulting from exocrine pancreatic insufficiency; excessive loss of electrolytes in sweat, which predisposes younger children to saline depletion episodes, especially when they present with vomits and diarrhea, or in the summer; 3 and chronic obstructive pulmonary disease. All these conditions usually have their onset on the 1st day of life, and lead to undernourishment and consequent delayed height and weight growth and bone maturation. 4 Clinical diagnosis of cystic fibrosis should be considered when: 1) there are cases of cystic fibrosis in siblings or relatives, or a history of unexplained deaths in the family with a clinical picture compatible with cystic fibrosis; 2) presence of meconium ileus; 3) repeated respiratory infections; 4) chronic obstructive pulmonary disease not related to smoking; 5) chronic diarrhea, especially steatorrhea; 6) height and weight deficits in children with reasonable food ingestion and respiratory and/or digestive symptoms; 7) edema and anemia in the 1st semester of life. 4 Diagnosis is safely confirmed by the sweat test: increased chloride and/or sodium excretion in sweat is diagnostic. Sweat is induced by pilocarpine iontophoresis, according to the Gibson-Cooke technique. Chloride concentrations > 60 mmol/l on two different occasions in samples of at least 100 mg of sweat confirm the diagnosis of cystic fibrosis. 2 Pulmonary diseases, such as repeated pneumonia and bronchiectasis, together with susceptibility to Pseudomonas aeruginosa and Staphylococcus aureus colonization, are the main longevity limiting factors in cystic fibrosis patients. 2 The objective of this study was to analyze: a) some of the characteristics that identify the population studied; b) their height and weight status; c) their present respiratory picture, including the analysis of main infectious agents and duration of colonization in the bronchial tree. We also analyzed laboratory findings for arterial gas (pH, PaO 2 , PaCO 2 and arterial/alveolar oxygen ratio) and for spirometry, especially total lung capacity (TLC), and forced expiratory volume in 1 second to forced vital capacity ratio (FEV1/FVC ratio), to assess, respectively, restrictive and obstructive impairment of the ventilatory function. These data were used to correlate arterial gas to spirometry. Arterial gas is routinely used at the Pediatrics Outpatient Service at Hospital de Clínicas, School of Medicine, Ribeirão Preto, as a parameter for the evaluation of pulmonary function of cystic fibrosis patients, while spirometry is not routinely used.
Patients and methods
This research project was approved by the Research Ethics Committee at Hospital de Clínicas, School of Medicine, Ribeirão Preto, Universidade de São Paulo. We retrospectively studied the medical records of 16 patients with cystic fibrosis and the prospective data on their arterial gas and spirometry. Both tests were performed in the Pneumology Laboratory at the Internal Medicine Department, School of Medicine, Ribeirão Preto, Universidade de São Paulo. Patients were not in an acute stage of pulmonary disease, that is, did not need to be hospitalized because of their respiratory problems, since they did not present any signs/symptoms, or signs and symptoms were not severe. There were female and male patients, 6 years old or older (age was limited due to the spirometry technique used), and they were followed up in the Pediatrics Outpatient Service at Hospital das Clínicas, School of Medicine, Ribeirão Preto, Universidade de São Paulo.
The protocol followed checked identification data (age, sex, race), sweat chloride (Cl -) concentrations, age at diagnosis, genotype, weight, height, microbiological analysis (microbial agent found in sputum and date of colonization), present clinical signs and symptoms, both intestinal (chronic diarrhea, steatorrhea, abdominal distention) and respiratory (dry cough, productive cough, dyspnea), and findings for arterial gas (especially the arterial/alveolar oxygen ratio) and spirometry (especially TLC and FEV1/FVC ratio).
Arterial gas was performed in one phase. Approximately 1 ml of arterial blood was obtained from the patient at rest, sitting and breathing room air. We used the Corning™ 178pH/Blood Gas Analyzer to analyze pH, PaCO 2 , PaO 2 , and the arterial/alveolar oxygen ratio.
The patients were sitting for the spirometry. The Maxi Modular Lung Analyzer Warren Collins with Helium Analyzer was used to record functional residual capacity (amount of air left in the lungs after one normal expiration), total lung capacity (maximum volume of air in the inflated lungs), FEV1/FVC ratio, and forced expiratory flow 25-75. Torres' 5 (1992) values were adopted as reference for our laboratory findings.
Statistical analyses performed were: a) average and standard deviation for gas parameters (pH, PaO 2 , PaCO 2 , and arterial/alveolar oxygen ratio) and spirometry parameters (total lung capacity and FEV1/FVC ratio); b) median and variance of patients' ages at the time this study was carried out, of their ages at diagnosis, and of Cl -concentrations in sweat; c) test of correlation between the PaO 2 variables versus the difference between predicted and observed values for FEV1 and total lung capacity. 6 
Results
The results of data analysis for the subjects of this study are presented in Table 1 . The median age was 114 months (9 years and 6 months); 93.75% were white and only one was a mulatto; 68.75% (11) were males; 81.25% (13) had the mixed form of the disease, i.e., showed both respiratory and gastrointestinal involvement, though 100% showed respiratory involvement; the median for chloride in sweat was 104.4 mEq/l; genotype for 56.25% (9) of the subjects was F508 deletion; and the median age at diagnosis was 15 months (1 year and 3 months). These patients were in the low height and weight percentiles: 31.25% were below the 5th percentile of the height/age ratio, and 37.5% were below the 5th percentile of the weight/age ratio according to the National Center for Health Statistics reference tables.
Productive cough was the most frequent symptom for the subjects in this study. All these patients had a positive sputum culture for a long time (minimum = 1 year; median = 6 years), either for Staphylococcus aureus (75% of the patients) or Pseudomonas aeruginosa (81.25%).
Arterial gas and spirometry findings (Table 2) show that 81.25% of the patients (all except patients 13, 14 and 16) presented alveolar capillary dysfunction. As TLC and FEV1/ FVC show, patients 1, 5, 8, 15 and 16 presented obstructive dysfunction, and patients 2, 3 and 7 presented obstructive and restrictive dysfunction. The other patients did not show any alterations in these parameters. Arterial gas successfully detected altered pulmonary function (alveolar capillary dysfunction) in 13 out of 16 patients (81.25%). Spirometry, on its turn, successfully detected altered pulmonary function in nine (56.25%) patients (five with obstructive dysfunction and four with obstructive and restrictive dysfunction).
Discussion
Cystic fibrosis was diagnosed too late for the patients in this study. The median age at diagnostic confirmation was 15 months (1 year and 3 months). The onset of the respiratory and/or gastrointestinal symptoms takes place around 3 months of age, and the delay in diagnosis may result from the overlapping of cystic fibrosis signs and symptoms with those of pathologies which are common in our environment, such as chronic diarrhea, undernourishment, and pulmonary infections. 7 A close association between height and weight deficits and pulmonary deterioration in cystic fibrosis patients is suggested in medical literature. [8] [9] [10] This study found a similar association. The height and weight deficit of the patients studied is associated with 100% of the respiratory symptoms and the long duration of bronchial tree colonization, which is one of the main limitations to patients' longevity. 2 Initial pulmonary alterations take place in the small airways and progress to the larger airways. Necropsies of patients as young as 4 months of age have revealed mucopurulent material, inflammatory infiltrate, submucosal Table 2 -Arterial gas and spirometry of cystic fibrosis patients glandular hypertrophy and epithelial metaplasia. The respiratory picture, in which the productive cough is the most prominent symptom, progresses to bronchiectasis. The pulmonary parenchyma is involved, but not as seriously as the airways. 1 A study with 29 cystic fibrosis patients, in which their spirometry data were compared at the average age of 6 months and then later at 5 years and 10 months (average), showed that patients were susceptible to hyperinflated lungs and small airway dysfunction, although there were no significant changes in the measurement of airway resistance. It also showed that external factors, such as the number and severity of respiratory infections (especially by Pseudomonas aeruginosa) affect both the clinical picture and the pulmonary function measurements. 11 Arterial gas detected changes in pulmonary function in 81.25% of the patients, and spirometry, in 56.25% (50% overlapping). These results contrast with cystic fibrosis patients up to 1 year old who still have their pulmonary function preserved. 12, 13 However, after 5 years of clinical follow-up, only one-fourth of these patients did not show any deterioration in pulmonary function. 14 We cannot, however, suggest that arterial gas alone is the more adequate test of pulmonary function for cystic fibrosis patients. The correlation of PaO 2 versus percentage of observed FEV1/FVC yields an inverse rank correlation coefficient (r=-0.54), which demonstrates that arterial gas and spirometry are two independent laboratory examinations to assess different components of pulmonary function: the former, hematosis and alveolar ventilation; the latter, total ventilation. As we reviewed the literature, [15] [16] [17] [18] we found, contradictorily, that the study of pulmonary function in cystic fibrosis patients favors the analysis of spirometry values only. Forced expiratory flow 25-75 and FEV1/FVC ratio have become standard parameters in the assessment of pulmonary function of these patients. 14 The forced expiratory flow 25-75 is the average flow of expired air during the central half of the forced vital capacity effort, measured in liters per second. The FEV1/FVC ratio is the volume of expired air in the 1st second of a maximal rapid expiratory effort, divided by the difference of the volume of air during a complete inspiration and expiration, measured at the mouth, with maximal rapid expiratory effort.
All the cystic fibrosis patients examined in this study showed some level of pulmonary involvement, at least chronic (longer than 1 year) bronchial tree colonization by agents such as Pseudomonas aeruginosa and/or Staphylococcus aureus.
Arterial gas detected a larger number of patients with pulmonary function alterations than spirometry. However, the two examinations were complementary for a good pulmonary function assessment of the patients studied.
